


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

UPDATED INFORMATION OF THE GROUP'S PRODUCTS

The board of directors (the "Board") of The United Laboratories International Holdings Limited (the "Company") is pleased to announce that it was notified by China State Food and Drug Administration ("SFDA") on 31 December 2010 that the applications of the Group's three insulin finished products, namely R(S20100013), 30R(20100014) and 50R(S20100015), were approved. Including the previously approved insulin finished product NS20090030 and insulin bulk medicine S20090031, total five insulin products of the Group have been approved by SFDA. It is expected that the relevant insulin products will be launched to the market soon.

In addition, the Group's production plant in Inner Mongolia after years of innovative research has a breakthrough in the production of bulk amoxicillin. The production of green amoxicillin with enzymatic method results a 100% of purity, no impurities and residual material, almost no production sewage and lower cost. It is the world's most advanced technology in production of bulk amoxicillin. It is expected that the product would be approved recently and will bring considerable return to the Company and its shareholders in future.

By Order of the Board of
**The United Laboratories
International Holdings Limited**
Choy Kam Lok
Chairman

Hong Kong, 4 January 2011

As at the date of this announcement, the Board comprises Mr. Choy Kam Lok, Ms. Peng Wei, Mr. Leung Wing Hon, Mr. Tsoi Hoi Shan, Ms. Zou Xian Hong, Ms. Zhu Su Yan and Mr. Fang Yuping as executive directors; Ms. Choy Siu Chit as non-executive director; and Mr. Chong Peng Oon, Mr. Huang Bao Guang and Mr. Song Ming as independent non-executive directors.